Erdafitinib/Bocco belongs to which generation of targeted drugs. How about it?

Erdafitinib (Erdafitinib) is a targeted drug that specifically targets fibroblast growth factor receptor (FGFR) mutations. Its emergence marks a new stage of precision in targeted therapy. Compared with early targeted drugs, erdafitinib belongs to the second generation of small molecule targeted drugs. Its core advantage is that it can selectively inhibit the kinase activity of FGFR family members, thereby blocking abnormal signaling pathways and inhibiting tumor cell proliferation and migration. This mechanism of targeting specific molecular abnormalities allows it to show higher efficacy and tolerability in the treatment of advanced urothelial cancer (bladder cancer) and other FGFR mutation-related tumors.

Second-generation targeted drugs generally have higher selectivity and lower non-specific toxicity than first-generation drugs. Most of the first-generation targeted drugs are broad-spectrum tyrosine kinase inhibitors, which have a wide range of effects but also have obvious side effects, and can easily lead to systemic toxic reactions. Erdafitinib achieves effective blocking of abnormal signals by accurately identifying and binding to FGFR mutation sites, while reducing damage to normal cells and improving the safety of long-term treatment for patients. Research shows that the emergence of second-generation targeted drugs has changed the patient's disease management model, making targeted therapy not only focus on short-term efficacy, but also pay more attention to long-term quality of life and chronic management.

In addition, the development background of erdafitinib shows that it is not only a second-generation targeted drug in terms of mechanism, but also embodies the concept of precision medicine. By screening tumors for molecular signatures, doctors can determine which patients are best suited to receive erdafitinib. This treatment model, unlike traditional chemotherapy or non-specific drugs, provides patients with a safer and more effective choice.

In general, erdafitinib/BOC is a second-generation targeted drug. Its precise mechanism of action, high selectivity and low toxicity give it unique advantages in the treatment of FGFR mutation-related tumors.

References：https://www.balversa.com/